DNA synthesis is the write step in the read-write-program story that powers the “Imperium” pitch. It is the process of assembling custom DNA sequences from scratch, letter by letter, and it is the step Adam O’Dell’s thesis says has just gotten dramatically faster. This explainer keeps the science and mechanics first, with Twist Bioscience as the leading example, and it clarifies the one number in the pitch you should treat with care.

Reading vs. Writing DNA

The field of genomics splits cleanly into two directions. Reading DNA is sequencing, the process of decoding the order of bases in an existing strand. Writing DNA is synthesis, the process of building a new strand in whatever order you specify. They are opposite operations, and they have moved at very different speeds.

Sequencing got cheap first. The cost of reading a human genome collapsed over two decades, which is why the pitch can correctly say DNA is “fast enough, cheap enough, and scalable enough” to matter. Synthesis, the writing step, has been the slower half of the pair, because building long, accurate strands of DNA is harder than reading them. That gap is exactly where the Imperium pitch aims its argument: the write step is finally catching up.

How Synthesis Works

At its core, DNA synthesis is a manufacturing process. The four chemical bases, adenine, cytosine, guanine, and thymine, are added one at a time in a specified order to build up a strand. The challenge is accuracy and length: every time you add a base, some fraction of the strands take the wrong one, and those errors compound as the strand grows, so longer sequences are much harder to build correctly.

The commercial service turns this into a product. A researcher submits a digital sequence, and the vendor prints the physical DNA, verifies it, and ships it back. Cost scales with length and complexity, and the companies that win are the ones that can produce longer, more accurate DNA at lower cost. That is a classic manufacturing race, and it is the economic engine underneath the whole synthetic-biology theme we explain in our synthetic biology piece.

The Silicon-Chip Leap

The specific advance the pitch celebrates belongs to Twist Bioscience. Where older methods synthesize DNA in plastic plates, Twist’s NanoWell approach prints DNA on silicon chips, packing thousands of microscopic wells onto a single chip so many different sequences can be built in parallel at once.

The pitch’s version of the advantage is a single sentence: Twist “processes DNA at 10,000 times the speed of the previous technology.” The chip approach is a real step change in throughput, and Twist’s partner list, which includes Amazon, Microsoft, Johns Hopkins, Illumina, and DARPA, reflects the fact that serious buyers treat the company as a genuine leader. The financial record backs up the story of a growing business: fifteen consecutive quarters of roughly 20% revenue growth and a position near break-even on adjusted cash flow.

The Honest Caveat

Here is the caveat our teardown flagged, and it matters. The “10,000 times faster” figure is a marketing number we could not independently verify. The underlying direction is real, DNA synthesis is getting faster and cheaper, but the specific multiple is best read as promotional shorthand rather than a measured benchmark.

There is a second layer of caution, too, and it is about the stock rather than the science. Twist trades at a premium in a competitive tools market, and that premium has drawn a Sell rating and a $45 target from BWS Financial. The technology and the stock are two different questions, and the honest way to hold them is separately. Our Twist Bioscience stock piece sorts out the valuation debate in full.

Why the Write Step Matters to Investors

Synthesis is the bottleneck that decides the pace of the entire field. If writing DNA is slow and expensive, then the software and applications built on top of it stay small. If writing DNA gets cheap, the apps layer, and the companies that sit in it, becomes the interesting part of the story, which is why the pitch also points at Ginkgo Bioworks as the software layer and Absci as the apps layer. We cover Ginkgo’s pivot and its risks in our Ginkgo Bioworks stock piece.

For an investor, the practical takeaway is simple. Watch the write step, because it is the constraint everything else depends on, and judge the specific names at the specific prices they actually trade at, not at the prices the pitch implies they are worth.

Where the Write Step Is Headed

The direction of travel is the strongest part of the pitch. DNA synthesis has tracked a falling cost curve for years, and the tooling around it keeps improving, with AI increasingly used to design better sequences and speed up protein discovery. That is a trend visible in the market today, not a forecast to take on faith.

What is harder to predict is who captures the value of that curve. Synthesis is a competitive tools market rather than a monopoly, and incumbents like Illumina, Thermo Fisher, and Danaher all hold a seat at the table. The write step is real and improving; the open question is whether any single company keeps enough of the economics to justify a premium multiple. That question, not the science, is where an investor’s homework actually begins.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.